


Epilepsia™

Official Journal of the International League Against Epilepsy

International Epilepsy Congress Abstract Issue



WILEY

wileyonlinelibrary.com/journal/epi



International League
Against Epilepsy

Cover

Cover image credit: Mesa Schumacher

This journal is listed in Index Medicus/MEDLINE, Current Contents/Life Sciences, Current Contents/Clinical Medicine, Neuroscience Citation Index, Reference Update, Science Citation Index, SciSearch/SCI Expanded, EMBASE/Excerpta Medica, Biological Abstracts, Chemical Abstracts Databases, Global Health, Derwent Journals Abstracted, PsychInfo/ Psychological Abstracts, BIOSIS, PASCAL, EBSCO, and CABS.

Epilepsia is a member of the Committee on Publication Ethics (COPE)

COPE COMMITTEE ON PUBLICATION ETHICS

Disclaimer

The Publisher, the International League Against Epilepsy, and Editors cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; the views and opinions expressed do not necessarily reflect those of the Publisher, International League Against Epilepsy, or Editors, neither does the publication of advertisements constitute any endorsement by the Publisher, International League Against Epilepsy, or Editors of the products advertised.

Copyright and Copying

Copyright © 2023 International League Against Epilepsy. All rights reserved. No part of this publication may be reproduced, stored or transmitted in any form or by any means without the prior permission in writing from the copyright holder. Authorization to copy items for internal and personal use is granted by the copyright holder for libraries and other users registered with their local Reproduction Rights Organisation (RRO), e.g. Copyright Clearance Center (CCC), 222 Rosewood Drive, Danvers, MA 01923, USA (www.copyright.com), provided the appropriate fee is paid directly to the RRO. This consent does not extend to other kinds of copying such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale. Special requests should be addressed to: permissions@wiley.com

Information for subscribers

Epilepsia is published in 12 issues per year. Institutional subscription prices for 2022 are:

Print & Online: US\$2893 (US), US\$3944 (Rest of World), €2558 (Europe), £2016 (UK). Prices are exclusive of tax. Asia-Pacific GST, Canadian GST/HST and European VAT will be applied at the appropriate rates. For more information on current tax rates, please go to <https://onlinelibrary.wiley.com/library-info/products/price-lists/payment>. The price includes online access to the current and all online back files for previous 5 years, where available. For other pricing options, including access information and terms and conditions, please visit <https://onlinelibrary.wiley.com/library-info/products/price-lists>. Terms of use can be found here: <https://onlinelibrary.wiley.com/terms-and-conditions>

Delivery Terms and Legal Title

Where the subscription price includes print issues and delivery is to the recipient's address, delivery terms are Delivered at Place (DAP); the recipient is responsible for paying any import duty or taxes. Title to all issues transfers FOB our shipping point, freight prepaid.

Claims for Missing or Damaged Print Issues

Our policy is to replace missing or damaged copies within our reasonable discretion, subject to print issue availability, and subject to the following terms: Title to all issues transfers Freight on Board ("FOB") to the address specified in the order; (1) Freight costs are prepaid by Wiley; and (2) Claims for missing or damaged copies must be submitted by the Customer or Subscription Agent within the claims window, as noted below.

Claims window - General

Claims for missing print issues must be sent to cs-agency@wiley.com (and the Subscription Agent or Customer may be referred to a society) within three months of whichever of these dates is the most recent: date of subscription payment; or date of issue publication.

Claims window - India

Both Subscription Agents and Customers in India have 48 hours after receipt of goods to confirm that all content listed on the packing label has been received. In the event of any discrepancy, SPUR Infosolutions, Wiley's delivery partner in India, needs to be notified within forty-eight (48) hours using this email address: support@spurinfo.com. All claims will be checked against SPUR Infosolutions delivery records before the claim is accepted. The above terms for Wiley's claims policy otherwise apply.

Back issues: Single issues from current and recent volumes are available at the current single issue price from cs-journals@wiley.com. Earlier issues may be obtained from Periodicals Service Company, 351 Fairview Avenue - Ste 300, Hudson, NY 12534, USA. Tel: +1 518 822-9300, Fax: +1 518 822-9305, Email: psc@periodicals.com
Epilepsia, (ISSN 0013-9580 [print] ISSN 1528-1167 [online]), is published monthly on behalf of the International League Against Epilepsy by Wiley Periodicals LLC, 111 River St., Hoboken, NJ 07030-5774.

Periodical Postage Paid at Hoboken, NJ and additional offices.

Postmaster: Send all address changes to EPILEPSIA, Wiley Periodicals LLC, C/O The Sheridan Press, PO Box 465, Hanover, PA 17331.

Publisher

Epilepsia is published by Wiley Periodicals LLC 101 Station Landing, Suite 300, Medford, MA 02155

Journal Customer Services: For ordering information, claims and any enquiry concerning your journal subscription please go to <https://wolsupport.wiley.com/s/contactsupport?tabset-a7d10=2> or contact your nearest office.

Americas: Email: cs-journals@wiley.com; Tel: +1 877 762 2974.

Europe, Middle East and Africa: Email: cs-journals@wiley.com; Tel: +44 (0) 1865 778315; 0800 1800 536 (Germany).

Germany, Austria, Switzerland, Luxembourg, Liechtenstein: cs-germany@wiley.com; Tel: 0800 1800 536 (Germany)

Asia Pacific: Email: cs-journals@wiley.com; Tel: +65 3165 0890.

Japan: For Japanese speaking support, Email: cs-japan@wiley.com.

Visit our Online Customer Help at <https://wolsupport.wiley.com/s/contactsupport?tabset-a7d10=2>

Production Editor: Vikranth Parthibhan (email: epi@wiley.com)

Advertising: For information on advertising, contact Kathleen Harrison, PMI, 212-904-0372, kharrison@pminy.com

Commercial reprints: Helane Silverman (email: hsilverman@wiley.com)

View this journal online at onlinelibrary.wiley.com/journal/epi

Wiley is a founding member of the UN-backed HINARI, AGORA, and OARE initiatives. They are now collectively known as Research4Life, making online scientific content available free or at nominal cost to researchers in developing countries. Please visit Wiley's Content Access - Corporate Citizenship site: <http://www.wiley.com/WileyCDA/Section/id-390082.html> Printed in the United States by The Sheridan Group.

Wiley's Corporate Citizenship initiative seeks to address the environmental, social, economic, and ethical challenges faced in our business and which are important to our diverse stakeholder groups. Since launching the initiative, we have focused on sharing our content with those in need, enhancing community philanthropy, reducing our carbon impact, creating global guidelines and best practices for paper use, establishing a vendor code of ethics, and engaging our colleagues and other stakeholders in our efforts.

Follow our progress at www.wiley.com/go/citizenship

Epilepsia accepts articles for Open Access publication. Please visit <https://authorservices.wiley.com/Author-resources/Journal-Authors/open-access/hybrid-open-access.html> for further information about OnlineOpen.

For submission instructions, subscription and all other information visit: <http://www.epilepsia.com>

EpilepsiaTM

Official Journal of the International League Against Epilepsy

Volume 64, Supplement 2, November 2023

International Epilepsy Congress Abstract Issue

TABLE OF CONTENTS

Volume 64, Supplement 2, November 2023

SUPPLEMENT ARTICLES

1

Satellite Symposium

doi: 10.1111/epi.17786

7

Abstracts

doi: 10.1111/epi.17787

571

Author Index

doi: 10.1111/epi.17788

- Sousa, A., 150
 Souza, M., 408, 409, 1585
 Souza-Santos, C., 101
 Spallaci, D., 396
 Spanou, M., 611
 Sparagana, S., 407
 Sparber, P., 1045
 Spasovska, T., 1052
 Specchio, N., 119, 327, 441, 528, 936, 987, 1017, 1156, 1216, 1231, **1439**, 1609, 1083
 Specht, U., 1192
 Speechley, K., 221
 Spencer, D., 112
 Sperling, M., 513
 Sperling, M.R., 190, 1006
 Sperti, G., 1107
 Spierer, R., 1476
 Spinelli, L., **516**, 824
 Spira, A., 731
 Spitz, G., 281
 Spitzer, H., 1197
 Spooner, C., 194
 Sprincean, M., 717, 901
 Spruill, T., 715
 Srinivas, N., **746**
 Srinivas, S., **1243**
 Srinivasan, V.M., 315
 Sriram, B., 409
 Srivastava, A., 778
 Srivastava, K., **1455**, **1456**
 Srivastava, S., 352
 Stabile, A., 1157
 Stack, J., **202**, **233**, **242**
 Staelens, S., 305
 Stahlhofer-Buss, T., 410
 Staley, K., 115, 1053
 Stanila, R., 234, 390, 498, 604, **904**, 1046
 Staunton, B., 326, 1207
 Stavropoulos, I., **1330**
 Steen, N.E., 1494
 Steensbjerre Møller, R., 352, 1545
 Stefan, H., 563
 Stefani, S., 315
 Stefanidi, A., 611
 Stefanos-Yakoub, I., **985**
 Stegmann, A., 1241
 Steinbacher, J., 121, 801, 803, 820
 Steinberg, A., 652
 Steinborn, B., 691
 Steinhoff, B.J., **117**, 118, 373, **534**, 1214
 Stephen, E., 695
 Stephens, E., 748
 Stephenson, S., 578
 Sterbova, K., 517
 Steriades, C., 519
 Sterlini, B., 109
 Stern, J., 496
 Stern, J.M., 90
 Stern, W., **293**, **301**
 Stevelink, R., **1505**
 Steven, D., 1067
 Stevens, S., 557
 Stipa, C., 659, 991
 Stirling, R., **347**, 790, 1590
 Stirling, R.E., 766
 Stivers, B., 1411
 St John, M., 1151
 Štillová, K., 1054
 Stöcker, T., 1351
 Stone, S., 870
 Straffi, M., 592
 Straka, B., 278
 Street, J., 1445
 Striano, P., 109, 247, 315, 387, 496, 517, 834, 869
 Strickland, T., **1291**
 Strigaro, G., 1251, **1339**
 Strøbæk, D., 1083
 Strobbé, G., 516
 Strowd, R., 537
 Struck, A., 1630
 Strug, L., 247, 982
 Strýček, O., **905**, 1054, 1115
 Strzelczyk, A., 117, **118**, 119, **373**, 523, 834, 1525
 Stunnenberg, B., 533
 Sturniolo, M., 494
 Stutely, J., 169, 911
 St. Wecker, P., 726
 Su, T., 564
 Su, T-Y., 298
 Sudachan, P., 787
 Sueiras, M., 1101
 Sueiras-Gil, M., 1485, 1491
 Sukhonosova, O., 725
 Suller Marti, A., **1065**, 1482
 Suller-Marti, A., **868**, 1067
 Sullivan, J., 169, 583, 735, 909, 911
 Sultan, H., 1490
 Sumangala, S., 744
 Sun, H., 531
 Sun, J., 207
 Sun, L., 1613
 Sun, M., 916
 Sun, Y., 654, 1012, 799
 Sundaram, S., 160, 345, 1601
 Sünkel, I., 523
 Sura Reddy, P., 65
 Suraweera, C., 257
 Surges, R., 530, 593, 603, 829, 840, 858, 859, 1025, 1026, 1116, 1328, 1331, 1336, 1340, 1351, 1361
 Suri, A., 291
 Suri, M., 869
 Suthar, R., 18
 Sutter, F., 451
 Suzuki, H., 1219
 Suzuki, J., 58
 Svanborg, E., 632
 Svendsen, T., 1184
 Svoboda, J., 972
 Sweeney, A., **1117**
 Sweeney, B., 812
 Sweeney, B.J., 833
 Sweeney, C.A.P., 589
 Sweeney, K., 326, 669, 1207, 1298
 Sweeney, K.J., 589
 Swinnen, L., **538**, 1520
 Swissa, E., 440
 Symonds, T., 612
 Synnott, C., **158**, 234, 390, 498, 904
 Syrbe, S., 1041
 Syvertsen, M., 247
 Szabo, J.P., 1634
 Szabó, J.P., 1606, **1617**
 Szaflarski, J., **549**, 1319
 Szaflarski, J.P., 117, 118, 406, **536**
 Szarek, N., 1014
 Szkop, M., 825, 1055
 Szmalec, A., 547
- T**
 Taati, B., 62
 Tabae Damavandi, P., **121**
 Tacheva, A., 542
 Tadiello de Moraes, H., 1592
 Taffoni, F., 870
 Tagliani, S., 1107
 Taherifard, E., 1451, 1561, 1451
 Tahir, A., 291
 Tahiri, A., 882
 Tailby, C., **1555**, **1557**
 Tajudeen, A., 1397
 Takahashi, R., 58, 251, 588, 1089, 1164
 Takaya, S., 251

a parent, to attempt IV access, and to determine the type of seizure. About half of the nurses correctly defined the epileptic seizure type in the case report. The nurses responded to the medical therapy they applied in the EDs, according to the phases of seizure intervention. According to the responses; in the first-line therapy; rectal diazepam was applied after that IM midazolam, IV diazepam, and IV midazolam were applied. In the second-line therapy; IV diazepam was applied after that IM midazolam, IV phenobarbital, and rectal diazepam were applied.

Conclusion: As a result of this study, while some of the practices for the management of epileptic seizures are correct, there are also some wrong interventions of the nurses.

1270 | The virtual epilepsy specialist nurse in prison – a service evaluation project

M Esposito¹, L Bruce¹, R Murphy¹, M Pierri¹

¹Cardiff and Vale UHB, Epilepsy, Cardiff, United Kingdom

Purpose: Many services needed to change the way health care was delivered due to the pandemic, this included the prison epilepsy clinic led by the epilepsy specialist nursing team. A service evaluation of the virtual service compared to a face to face clinic held in the prison's healthcare suite was carried out between 2020 -2023. Cardiff prison has capacity for up to 820 men aged 18 and above. People with epilepsy should have access to specialist care and support (NICE 2019, Welsh Government 2019). Quality statements support the well-being of prisoners and ensure safe and effective care (NICE 2017). Providing healthcare to people in prison has challenges and this was highlighted more so during the height of the pandemic. The prevalence of seizures and epilepsy in prison is four times higher than the general population, with lower engagement in healthcare (Marshall et al. 2001, Birmingham 2003). It is evident the prison patient population are one of the most vulnerable groups regarding healthcare.

Method: A retrospective evaluation of initial referral to time of review for face to face and virtual clinics and a retrospective review of attendance to the face to face and virtual clinic between 2020 -2023. Written feedback from prison officers, prison healthcare staff on the virtual clinic and use of the resources and feedback from the men using the clinic.

Results: Reduced waiting list times 9-42 days from referral to review by epilepsy specialist nurse compared to 3-6 months when the clinic was conducted in the prison. Improved attendance rate with the virtual clinic from 50% to 80% Positive feedback from healthcare staff and patients with a request to continue the virtual service despite the lifting and easing of restrictions.

Conclusion: Improved access to epilepsy specialist service. Reduced waiting times. Improved attendance rate. Efficient use of resources.

Paediatric Epileptology

725 | Comparison of clinical, electroencephalographic and tomographic data in children with controlled and non-controlled epilepsy

O Sukhonosova¹, T Litovchenko¹

¹Kharkiv Medical Academy of Postgraduate Education, Department of Neurology and Child Neurology, Kharkiv, Ukraine

Purpose: To analyze importance of etiology of neonatal seizures in formation of epilepsy in children of early age.

Method: There were 236 children at the age of 3 who suffered neonatal seizures under supervision. All patients underwent somatic and neurological examination, EEG, EEG video monitoring, MRI of the brain, laboratory methods with metabolic control, genetic testing and virological examination in the neonatal period and later

Results: During the survey etiological factors of neonatal seizures were determined: hypoxic-ischemic encephalopathy (47%), intracranial hemorrhage and vascular diseases (11%), prenatal infections (7%), postnatal neuroinfections (3%), metabolic electrolyte disorders (4%), developmental disorders (dysgenesis) (8%), facomatosis (2%), withdrawal syndrome (1%), congenital metabolic disorders (2%), chromosomal syndromes (1%), congenital tumors (1%), benign neonatal seizures (3%), somatic diseases (1%), postnatal trauma (1%), not specified (8%). According to the classification of etiology of epilepsy (32nd International Congress on Epilepsy, 2017) all patients were distributed as follows: structural -67%, genetic - 4%, infectious - 10%, metabolic - 4%, immunological - 1%, not specified - 8%, mixed - 6%. According to outcomes regarding the formation of epilepsy and neurological deficiency all children at the age of 3 were divided into 3 groups: (1) without seizures up to 3 years of age and without formation of a neurological deficiency (61%); (2) with formation of epilepsy, in which medication remission was achieved, and moderate neurological deficiency (16%); (3) with formation of drug-resistant epilepsy and severe neurological deficiency (23%).

Conclusion: Patients in the 1st group had neonatal seizures due to light hypoxic-ischemic encephalopathy, somatic diseases and transient metabolic disorders. In the 2nd group causes of neonatal seizures and further epilepsy

were moderate hypoxic-ischemic encephalopathy, postnatal neuroinfections and postnatal trauma. Patients with formation of drug-resistant epilepsy more often had severe hypoxic-ischemic encephalopathy, intracranial hemorrhage, congenital malformations, prenatal infections, congenital metabolic disorders, developmental disorders.

29 | The new ILAE definition of Lennox-Gastaut syndrome: practical implications and limitations

A Asadi-Pooya^{1,2}

¹Shiraz University of Medical Sciences, Shiraz, Iran, Islamic Republic of, ²Thomas Jefferson University, Philadelphia, United States

Purpose: There are three major changes in the new definition of Lennox-Gastaut syndrome (LGS) compared with the traditional definition: (1) onset prior to 18 years, (2) must include tonic seizure, (3) generalized slow spike-waves (SSW) and (instead of or) generalized paroxysmal fast activity (GPFA) on electroencephalography (EEG). We investigated the practical implications and potential limitations of the new LGS definition based on a large cohort of patients in an exploratory study.

Method: This was a retrospective database study. All patients with an electro-clinical diagnosis of LGS (based on its traditional definition) at the outpatient epilepsy clinic at Shiraz University of Medical Sciences, Shiraz, Iran were included (from 2008 until 2020). Patients were reclassified based on the new definition of LGS.

Results: In total, 3737 patients were registered. Based on its traditional definition, 300 patients were diagnosed as having LGS. According to the new definition of LGS, only 96 patients (32% of the traditional cohort) had LGS. One patient had an age at onset of 21 years; 29 patients (9.7%) did not have SSW in their EEGs; 139 people (46.3%) did not have GPFA in their EEGs; and, 111 patients (37%) did not report having tonic seizures.

Conclusion: The new ILAE definition of LGS has some important practical implications and limitations. Before reinforcing and making this new definition compulsory in future research and clinical practice, more work is needed to enlighten various aspects of such changes in the definition of this epilepsy syndrome.

39 | Serial electroencephalographic findings before the onset of juvenile myoclonic epilepsy: a case series

J Tohyama^{1,2}, Y Kobayashi¹, A Hiraiwa^{3,1}, M Hojo¹

¹NHO Nishiniigata Chuo Hospital, Department of Child

Neurology, Niigata, Japan, ²Niigata University Medical and Dental Hospital, Department of Medical Genetic Counseling, Niigata, Japan, ³University of Toyama, Department of Pediatrics, Toyama, Japan

Purpose: We aimed to delineate the clinical and electroencephalographic transition in patients with juvenile myoclonic epilepsy who were followed-up long-term before onset of juvenile myoclonic epilepsy.

Method: We enrolled juvenile myoclonic epilepsy patients whose course of epilepsy had been observed for more than five years before the onset of juvenile myoclonic epilepsy, those who had undergone electroencephalogram recording more than twice before the onset of juvenile myoclonic epilepsy, and those who had terminated antiseizure medications for at least two years before the onset of juvenile myoclonic epilepsy. Patients who had transitioned from childhood absence epilepsy to juvenile myoclonic epilepsy were excluded. We retrospectively reviewed the medical records and neurophysiological data of the patients.

Results: Four patients met the inclusion criteria. One patient was diagnosed with febrile seizures during childhood, and the remaining three had transitioned to juvenile myoclonic epilepsy from other epileptic disorders, such as self-limited epilepsy with autonomic seizures, genetic epilepsy with febrile seizure plus, or non-specific genetic generalized epilepsy. All had generalized spike-wave discharges or photoparoxysmal responses for more than two years before onset of juvenile myoclonic epilepsy.

Conclusion: Generalized spike-waves on electroencephalogram during the course of any type of epilepsy or febrile seizure may be a risk factor for developing juvenile myoclonic epilepsy. When generalized spike-waves are present during childhood in individuals with febrile seizures or pediatric epilepsy, follow-up examinations and careful clinical interviews are crucial.

41 | Efficacy of steroids in seizure control and dipole stabilisation in drug resistant electrical status epilepticus in sleep due to structural cause

N Balaram¹, J Jose¹, A Gafoor¹, S B¹

¹Government Medical College, Neurology, Kozhikode, India

Purpose: To devise objective measures to evaluate the role of steroids on dipole stabilisation and seizure control in Electrical Status Epilepticus in Sleep due to structural causes.

Method: 20 children aged 2-12 years with drug resistant epilepsy and ESES with Spike-wave index > 50% and